AXL and chronic myelogenous leukemia, BCR-ABL1 positive: Other studies have implicated PKCα and β as regulators of AXL expression based upon the observation that treatment of imatinib-resistant CML cell lines with a PKC inhibitor leads to decreased AXL [90].